These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 912511)

  • 21. Osteopenia during long-term haemodialysis: response to vitamin D3 analogues.
    Muirhead N; Adami S; Fraser RA; Catto GR; Edward N; O'Riordan JL
    Proc Eur Dial Transplant Assoc; 1981; 18():567-72. PubMed ID: 6895786
    [No Abstract]   [Full Text] [Related]  

  • 22. Long-term experience of alfacalcidol in renal osteodystrophy.
    Sharman VL; Brownjohn AM; Goodwin FJ; Hately W; Manning RM; O'Riordan JH; Papapoulos SE; Marsh FP
    Q J Med; 1982; 51(203):271-8. PubMed ID: 7146311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence that different vitamin D sterols have qualitatively different effects in man.
    Rasmussen H; Bordier P
    Contrib Nephrol; 1980; 18():184-91. PubMed ID: 7353375
    [No Abstract]   [Full Text] [Related]  

  • 24. 1 alpha-hydroxycholecalciferol in hemodialysis renal osteodystrophy. Adverse effects of anticonvulsant therapy.
    Pierides AM; Kerr DN; Ellis HA; Peart KM; O'Riordan JL; DeLuca HF
    Clin Nephrol; 1976 Apr; 3(2):189-96. PubMed ID: 819195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Immunoreactive parathyroid hormone, 25-hydroxycalciferol and bone histology in renal osteodystrophy (author's transl)].
    Offermann G; Schaefer K; Schulz A; Delling G
    Klin Wochenschr; 1976 Jul; 54(13):625-32. PubMed ID: 940299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of 1 alpha-hydroxyvitamin D3 on experimental uremic renal osteodystrophy in rats induced by Na-sulfacetylthiazole.
    Okano K; Nakai R; Tomori T; Yoshikawa M
    Endocrinol Jpn; 1978 Dec; 25(6):553-9. PubMed ID: 751801
    [No Abstract]   [Full Text] [Related]  

  • 27. The effect of 1alpha-hydroxyvitamin D3 on calcium and mineral content of bone in renal osteodystrophy.
    Junor BJ; Catto GR
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():131s-138s. PubMed ID: 606411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 1,25-dihydroxycholecalciferol in patients with chronic renal failure.
    Henderson RG; Ledingham JG; Norman AW; Oliver DO; Preston C; Russell RG; Small DG; Smith R; Warner GT; Woods CG
    Proc Eur Dial Transplant Assoc; 1973; 10(0):202-9. PubMed ID: 4802654
    [No Abstract]   [Full Text] [Related]  

  • 29. Fluoride and dialysis osteodystrophy: results of a double-blind study.
    Oreopoulos DG; Taves DR; Rabinovich S; Meema HE; Murray T; Fenton SS; deVeber GA
    Trans Am Soc Artif Intern Organs; 1974; 20A():203-8. PubMed ID: 4615422
    [No Abstract]   [Full Text] [Related]  

  • 30. Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol.
    Kanis JA; Henderson RG; Heynen G; Ledingham JG; Russell RG; Smith R; Walton RJ
    Arch Dis Child; 1977 Jun; 52(6):473-81. PubMed ID: 879833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.
    Muirhead N; Catto GR; Edward N; Fraser RA; O'Riordan JL; Papapoulos SE; Adami S
    Proc Eur Dial Transplant Assoc; 1980; 17():543-7. PubMed ID: 6972529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal osteodystrophy in early chronic renal failure.
    Suzuki M; Hirasawa Y
    Contrib Nephrol; 1980; 22():28-38. PubMed ID: 7398337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum calcium, phosphate and alkaline phosphatase and morphometric bone examinations in 30 patients with renal insufficiency.
    Duursma SA; Visser WJ; Mees EJ; Njio L
    Calcif Tissue Res; 1974; 16(2):129-38. PubMed ID: 4447892
    [No Abstract]   [Full Text] [Related]  

  • 34. A trial of calcitonin therapy in renal osteodystrophy.
    Delano BG; Baker R; Gardner B; Wallach S
    Nephron; 1973; 11(5):287-93. PubMed ID: 4753519
    [No Abstract]   [Full Text] [Related]  

  • 35. 1alpha-hydroxychloecalciferol treatment of long-term hemodialyzed patients. Effects on mineral metabolism, bone mineral content and bone morphometry.
    Nielsen HE; Melsen F; Christensen MS; Hansen HE; Rodbro P; Johannsen A
    Clin Nephrol; 1977 Oct; 8(4):429-34. PubMed ID: 923161
    [No Abstract]   [Full Text] [Related]  

  • 36. Variable response to long-term 1alpha-hydroxycholecalciferol in haemodialysis osteodystrophy.
    Pierides AM; Ellis HA; Simpson W; Dewar JH; Ward MK; Kerr DN
    Lancet; 1976 May; 1(7969):1092-5. PubMed ID: 57505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Long-term treatment of renalosteodystrophy with 1 alpha-hydroxycholecalciferol].
    Marco Franco JE; Alarcón Zurita A; Pizá Buñola C; Morey Molina A; Bestard Palmer J; Mairata Bosch S; Dalmau Diana M
    Rev Clin Esp; 1982 Jan; 164(1):33-5. PubMed ID: 7071401
    [No Abstract]   [Full Text] [Related]  

  • 38. [Therapy of uremic osteopathy. II. Effect of 5,6-trans-25-hydroxycholecalciferol in terminal kidney insufficiency].
    von Herrath D; Kraft D; Grigoleit HG; Schaefer K
    Dtsch Med Wochenschr; 1973 Jul; 98(28):1379-81. PubMed ID: 4197778
    [No Abstract]   [Full Text] [Related]  

  • 39. Renal osteodystrophy and its treatment.
    Duursma SA; Mees EJ
    Neth J Med; 1973; 16(2):101-7. PubMed ID: 4705764
    [No Abstract]   [Full Text] [Related]  

  • 40. A possible role for propranolol in the treatment of renal osteodystrophy.
    Caro JF; Besarab A; Burke JF; Glennon JA
    Lancet; 1978 Aug; 2(8087):451-4. PubMed ID: 79809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.